Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus From Birth
This article, published in The New England Journal of Medicine, reports the results of a study in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB). Healthy newborns received three doses of the vaccine, which was administered according to a neonatal vaccine schedule or an infant schedule, or placebo. The study found that the vaccine efficacy was 75 percent in the neonatal schedule group, 51 percent in the infant-schedule group, and 63 percent in the neonatal-schedule and infant-schedule groups combined. The authors concluded that RV3-BB was efficacious in preventing severe rotavirus gastroenteritis when administered according to a neonatal or an infant schedule.
Author: Bines JE, Thobari JA, Satria CD, et al.
» Visit web page (English)
(Located at www.nejm.org)
Citation: Bines JE, Thobari JA, Satria CD, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. The New England Journal of Medicine. 2018;378:719–730.
Resource types: Peer-reviewed journal